These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 23692526)

  • 1. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
    Nitti VW; Khullar V; van Kerrebroeck P; Herschorn S; Cambronero J; Angulo JC; Blauwet MB; Dorrepaal C; Siddiqui E; Martin NE
    Int J Clin Pract; 2013 Jul; 67(7):619-32. PubMed ID: 23692526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Ikeda Y; Ohkawa S
    BJU Int; 2014 Jun; 113(6):951-60. PubMed ID: 24471907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
    Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
    Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
    Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE
    BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
    Nitti VW; Chapple CR; Walters C; Blauwet MB; Herschorn S; Milsom I; Auerbach S; Radziszewski P
    Int J Clin Pract; 2014 Aug; 68(8):972-85. PubMed ID: 24703195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
    BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.